This page contains the latest news articles from newspapers across the United States and Canada regarding the dangers of Celebrex.

First Celebrex Lawsuit Going to Trial

CNN
February 27, 2006

The first Celebrex lawsuit in the country, filed by a stroke survivor against the drug giant Pfizer, is going to trial this year.

Rosie Ware, a 53-year-old Alabama resident who had suffered from hypertension, was taking the arthritis painkiller Celebrex when she suffered a stroke in February, 2005, and she sued the maker of the drug, Pfizer, according to plaintiff law firm Beasley Allen.

The case has been set for trial on June 6, 2006 at the Circuit Court of Barbour County in Alabama, according to Jere Beasley, the litigator for the plaintiff.


Another Caution on Vioxx, Celebrex

CNN
November 13, 2005

Merck's Vioxx, Pfizer's Celebrex and similar painkillers increase the risk of death among patients who have already survived a previous heart attack, especially when taken in high doses, according to data released Sunday at the American Heart Association conference here.

Patients who have heart disease should not use these types of drugs, called COX-2 inhibitors, according to Dr. Gunnar Gislason, a research fellow at Bispebjerg University Hospital in Copenhagen and the lead independent researcher in the study, which was funded by the Danish Heart Foundation and the Danish Pharmaceutical Association.

Bextra Taken Off Market; Celebrex Gets Warning

WebMD
April 7, 2005

The popular arthritis drug Bextra will be pulled from the U.S. market under a decision issued by the FDA Thursday.

FDA officials say they asked Pfizer the drug's market to remove it from U.S. pharmacies because its risks of heart, stomach, and skin problems clearly outweighed its benefits.

FDA: Consider Alternative to Celebrex

CNN
December 17, 2004

With a new study that indicates the nation's leading arthritis painkiller could raise the risk of heart attacks, the Food and Drug Administration advised doctors Friday to consider "alternative therapy" to Celebrex.

Earlier Friday, drug giant Pfizer Inc. said it had no plans to pull the painkiller off the market despite the data that showed patients using the drug in a long-term cancer study had increased cardiovascular risks.